ReviewGlobal heart2026
Implementing the World Health Organization Guidelines for Rheumatic Heart Disease in Highly Endemic Settings: Balancing Evidence with Reality.
Review in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, the World Health Organization (WHO) released rheumatic heart disease (RHD) guidelines; however, implementation in highly endemic countries remains challenging. The severe nature of RHD in such areas necessitates adopting pragmatic approaches to improve diagnostic yield. The WHO continues to recommend the Jones Criteria for the diagnosis of acute rheumatic fever, even though these criteria have been shown to miss up to 10% of cases. Using simplified clinical criteria is expected to have better sensitivity at the level of frontline health workers. The WHO recommendation to use handheld echocardiography for diagnosis of RHD is a crucial asset for secondary and tertiary prevention of RHD; however, implementation of this strategy might be hampered by limited availability and the need for expert training. While benzathine penicillin G remains the cornerstone of RHD treatment, as recommended by the WHO, persistent issues related to its availability and proper administration techniques need to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.